A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06818812

Title field or adapter rule

{'original_value': 'A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:27.025916+00:00

Published At

2026-08-25T00:00:00+00:00

Record Updated At

2026-08-25

Source Retrieved At

2026-10-31T22:17:58.991924+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Solid Tumors"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-08-25", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06818812"

protocolSection.identificationModule.officialTitle

"A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Solid Tumors (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Part 1a: Dose Escalation monotherapy', 'Part 1b: Dose Expansion monotherapy', 'Part 1c: Pharmacodynamic cohort', 'Part 1d: Food-Effect', 'Part 2a: Dose Escalation combination', 'Part 2b: Dose Expansion combination'], 'description': 'INCB186748 will be administered at protocol defined dose.', 'name': 'INCB186748', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 2a: Dose Escalation combination', 'Part 2b: Dose Expansion combination'], 'description': 'Cetuximab will be administered at protocol defined dose.', 'name': 'Cetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 2a: Dose Escalation combination', 'Part 2b: Dose Expansion combination'], 'description': 'GEMNabP will be administered at protocol defined dose.', 'name': 'GEMNabP', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part 2a: Dose Escalation combination', 'Part 2b: Dose Expansion combination'], 'description': 'mFOLFIRINOX will be administered at protocol defined dose.', 'name': 'mFOLFIRINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• INCB186748 (protocolSection.armsInterventionsModule.interventions[].name)
• Cetuximab (protocolSection.armsInterventionsModule.interventions[].name)
• GEMNabP (protocolSection.armsInterventionsModule.interventions[].name)
• mFOLFIRINOX (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.